CN105969903B - The diagnosis and treatment product of hypopharyngeal cancer biomarker - Google Patents
The diagnosis and treatment product of hypopharyngeal cancer biomarker Download PDFInfo
- Publication number
- CN105969903B CN105969903B CN201610601139.0A CN201610601139A CN105969903B CN 105969903 B CN105969903 B CN 105969903B CN 201610601139 A CN201610601139 A CN 201610601139A CN 105969903 B CN105969903 B CN 105969903B
- Authority
- CN
- China
- Prior art keywords
- incenp
- gene
- albumen
- expression
- hypopharyngeal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses the molecular markers that INCENP gene can be used as hypopharyngeal cancer diagnosis, the experiment proves that: compared with normal control tissue, INCENP gene expression quantity in hypopharynx cancerous tissue is low.The invention also discloses the drugs that INCENP gene can be used for preparing treatment hypopharyngeal cancer.Research achievement of the invention provides a kind of new hypopharyngeal cancer methods for clinical diagnosis, while providing a kind of drug new target drone for treating hypopharyngeal cancer.
Description
Technical field
The present invention relates to diagnosing tumor, treatment, prediction prognosis fields, more particularly it relates to detect INCENP
Abnormal is diagnosing tumor, the prediction method of prognosis of means；And the tumor therapeutic agent of activation INCENP gene or protein.
Background technique
Hypopharynx cancer morbidity is lower, and country's statistics accounts for the 0.15%-0.24% of whole body malignant tumour, and it is pernicious swollen to account for incidence
The 2% of tumor.It is generally believed that hypopharyngeal cancer is identical as laryngocarcinoma pathogenic factors, including tobacco and wine stimulation, virus infection, ionising radiation, something lost
Pass, trophic disturbance and body's immunity decline etc., the two original site adjoins, and treatment method is also similar, mainly with operation or
The complex treatments such as operation+radiotherapy, chemotherapy, but prognosis differs greatly, and 5 years survival rates of hypopharyngeal cancer are 26%-47% after complex treatment,
And laryngocarcinoma is 70%-90% or more.In recent years, with the rapid development of molecular biology, people gradually recognize the cancer of cell
Change is that a multifactor, multistage process in the different phase of canceration has different genes to change, thus to explain
Generation, development and the Prognostic Factors of bright hypopharyngeal cancer, it is necessary to be studied at the genetic level.
Summary of the invention
One of the objects of the present invention is to provide one kind to be diagnosed down by detection INCENP gene or protein expression difference
The method of pharynx cancer.
The second object of the present invention is to provide one kind by detection INCENP gene or protein expression difference to predict down
The method of pharynx cancer prognosis.
The third object of the present invention is that providing a kind of treat by activation INCENP gene or INCENP albumen swallows
The method of cancer.
The fourth object of the present invention is to provide a kind of method for screening the drug for the treatment of hypopharyngeal cancer.
The fifth object of the present invention is to provide a kind of for treating the drug of hypopharyngeal cancer.
To achieve the goals above, present invention employs following technical solutions:
The present invention provides the products of detection INCENP gene or INCENP albumen in preparing hypopharyngeal cancer diagnostic tool
Purposes.
The present invention also provides the products of detection INCENP gene or INCENP albumen to predict hypopharyngeal cancer prognosis work in preparation
Purposes in tool.
Further, the product of the detection INCENP gene or INCENP albumen includes detection INCENP gene or INCENP
The product of the expression of albumen.The product includes that can combine the nucleic acid of INCENP gene or can combine INCENP egg
White substance (such as antibody).The nucleic acid is able to detect the expression of INCENP gene；The substance is able to detect
The expression of INCENP albumen.
The product of detection INCENP gene of the invention can play its function based on the known method of nucleic acid molecules is used:
As PCR, such as Southern hybridization, Northern hybridization, dot blot, fluorescence in situ hybridization (FISH), DNA microarray, ASO method,
High-flux sequence platform etc..It can qualitatively, quantitatively or semi-quantitatively implement analysis using the product.
Include that nucleic acid in the said goods can be obtained by chemical synthesis, or by containing from biomaterial preparation
It is expected that the gene of nucleic acid, then using primer amplification designed for amplification expectation nucleic acid, it is obtained.
Further, the PCR method is known method, for example, ARMS (Amplification Refractory
Abruptly-changing system is not answered in Mutation System, amplification) method, RT-PCR (reverse transcriptase-PCR) method, nesting PCR method etc..Amplification
Nucleic acid can be by using dot blotting hybridization method, Surface Plasmon Resonance (SPR method), PCR-RFLP method, original position RT-PCR
Method, PCR-SSO (sequence specific oligonucleotide) method, PCR-SSP method, AMPFLP (amplifiable fragment length polymorphism) method,
MVR-PCR method and PCR-SSCP (single-strand conformation polymorphism) method detect.
Nucleic acid recited above includes the primer for expanding INCENP gene, and the primer for including in product can be by passing through
Synthesis is learned to prepare, by using those skilled in the art will know that method be suitably designed with reference to Given information, and pass through
It is prepared by chemical synthesis.
In specific embodiments of the present invention, the nucleic acid is amplimer used in QPCR experiment, the primer
Sequence such as SEQ ID NO.1 (positive sequence) and SEQ ID NO.2 (reverse sequence) shown in.
Nucleic acid recited above may also include probe, and the probe can be prepared by chemical synthesis, by using this
The method that field technical staff knows appropriately is designed with reference to Given information, and is prepared by chemical synthesis, or can lead to
The gene for containing desired nucleic acid sequence from biomaterial preparation is crossed, and is expanded using the primer designed for amplification expectation nucleic acid sequence
Increase it to prepare.
The product of detection INCENP albumen of the invention can play its function: example based on the known method of antibody is used
It such as, may include ELISA, radioimmunoassay, immunohistochemical method, western blot etc..
The product of detection INCENP albumen of the invention includes the antibody or its segment for specifically binding INCENP albumen.It can
To use the antibody or its segment of any structure and size, immunoglobulin class, origin etc., as long as it is in conjunction with target protein
It can.The antibody or its segment for including in testing product of the invention can be monoclonal or polyclonal.Antibody fragment refers to guarantor
Stay peptide of the antibody to the active antibody of the combination of antigen a part of (Partial Fragment) or containing antibody a part.Antibody fragment can be with
Including F (ab ')2, Fab ', Fab, scFv (scFv), disulphide bonding Fv (dsFv) or its polymer, the area dimerization V
(double antibody) or peptide containing CDR.The product of detection INCENP albumen of the invention may include encoding antibody or encoding antibody
The isolated nucleic acid of the amino acid sequence of segment, the carrier comprising the nucleic acid, and carry the cell of the carrier.
Antibody can be obtained by the way that well known to a person skilled in the art methods.For example, preparation retains target all or in part
The mammalian cell expression vector of their polynucleotides of the polypeptide or integration coding of protein is as antigen.Exempted from using antigen
After epidemic disease animal, from the immune animal adaptive immune cell of process and myeloma cell is merged to obtain hybridoma.Then from hybridization
Tumor culture collects antibody.It finally can be real by using antibody of the INCENP albumen for being used as antigen or part thereof to acquisition
Antigentic specificity purifying is applied to obtain the monoclonal antibody for INCENP albumen.Polyclonal antibody can be prepared as follows: with
Identical antigen-immunized animal above collects blood sample from by immune animal, serum is isolated from blood, is then made
Implement antigentic specificity to serum with above-mentioned antigen to purify.It can be by the antibody that is obtained with enzymatic treatment or by using acquisition
The sequence information of antibody obtains antibody fragment.
The combination of marker and antibody or its segment can be implemented by method as commonly known in the art.For example, can
With following fluorescent marker protein or peptide: clean protein or peptide with phosphate buffer, addition DMSO, buffer, etc. standards
Standby dyestuff, then mixed solution, then at being placed at room temperature for 10 minutes.In addition, the labelling kit of commercialization can be used in label, it is all
Such as biotin labeling reagent box, such as biotin labeling reagent box-NH2, biotin labeling reagent box-SH
(DojindoLaboratories)；Alkali phosphatase enzyme mark kit such as alkali phosphatase enzyme mark kit-NH2, alkaline phosphorus
Sour enzyme labelling kit-SH (Dojindo Laboratories)；Peroxidase labelling kit such as peroxidase mark
Remember kit-NH2, peroxidase labelling kit-NH2 (Dojindo Laboratories)；Phycobniliprotein labelled reagent
Box such as phycobniliprotein labelling kit-NH2, phycobniliprotein labelling kit-SH, B- phycoerythrin labelling kit-NH2,
B- phycoerythrin labelling kit-SH, R-PE labelling kit-NH2, R-PE labelling kit SH
(DojindoLaboratories)；Fluorescent labeling reagent box such as fluorescein labelling kit-NH2, HiLyte Fluor (TM)
555 labelling kit-NH2,647 labelling kit-NH2 of HiLyte Fluor (TM) (Dojindo Laboratories)；And
DyLight 547 and DyLight647 (Techno Chemical Corp.), Zenon (TM), Alexa Fluor (TM) antibody
Labelling kit, Qdot (TM) antibody labeling kit (Invitrogen Corporation) and EZ- marker protein mark
Remember kit (Funakoshi Corporation).For correct labeling, suitable instrument can be used to detect by label
Antibody or its segment.
As the sample according to testing product of the invention, the tissue sample for example obtained from biopsy subject can be used
Or fluid.Sample is not particularly limited, as long as it is suitable for measurement of the invention；For example, it may include tissue, blood, blood plasma,
Serum, lymph, urine, serous cavity liquid, spinal fluid, synovia, aqueous humor, tear, saliva or its fraction or treated material
Material.
In specific embodiments of the present invention, tissue of the sample from subject.
In the present invention, " prognosis " refers to mistake of the tumor patient after inhibiting by surgical procedure etc. or alleviating tumour growth
Journey or result.In the present specification, prognosis can be by surgical procedure inhibit or alleviate tumour growth after 1,2,3,4,5,6,
7,8,9,10,15,20 years or more long when life state.Prognosis can be by checking biomarker, that is, INCENP albumen or volume
The gene of code INCENP albumen is predicted.Prognosis prediction can be performed such that according to biomarker with or without or increasing
Or reduce, determine that the prognosis of patient is good or bad, or determine the probability of good prognosis or poor prognosis.
In the present invention, " prognosis bona " refer to inhibit or alleviate for patient by surgical procedure etc. tumour growth it
Afterwards, patient's long-term (such as 3,5,6,7,8,9,10,15,20 years or longer) does not have critical condition.Alternatively, good prognosis can anticipate
Refer to and survives in such long-time, sent out again without transfer, without recurrence or nothing.For example, prognosis bona can mean at least 3 years or outstanding
It is to survive at least 5 years, preferably without transfer or recurrence.The most preferred state of prognosis bona is survival for a long time without disease.Such as
Used herein, " prognosis bona " can also include any such state, wherein it can be found that disease such as shifts, still
It is pernicious low and do not severely impact survival ability.
In the present invention, " prognosis mala " refers to that patient is short after inhibiting or alleviating tumour growth by surgical procedure etc.
Fatal condition occurs in period (such as 1,2,3,4,5 year or shorter).Alternatively, poor prognosis refers in such short-term extremely
It dies, shift, recur or sends out again.For example, poor prognosis can mean Preventive or dead at least 3 years or especially at least 5 years
It dies.
Prediction prognosis is referred to the process of prediction status of patient or as a result, is not meant to be predicted with 100% accuracy
The process or result of status of patient.Prediction prognosis refers to whether a possibility that determining certain processes or result increases, and simultaneously unexpectedly
Taste by determining a possibility that certain processes or result occurs or not compared with certain processes or result.Such as this
For invention, in the present invention in the horizontal patient reduced of INCENP gene or INCENP albumen, with the trouble for not showing this feature
Person compares, and more likely observes particular procedure or result.
Further, it is described detection INCENP gene or INCENP albumen product can be detection INCENP gene or
The reagent of INCENP albumen is also possible to include kit, chip, test paper of the reagent etc., is also possible to using the examination
The high-flux sequence platform of agent.
The present invention also provides a kind of tool for diagnosing hypopharyngeal cancer, the tool is able to detect INCENP gene or INCENP
The expression of albumen.The tool includes the nucleic acid that can combine INCENP gene or the object that can combine INCENP albumen
Matter (such as antibody).The nucleic acid is able to detect the expression of INCENP gene；The substance is able to detect INCENP albumen
Expression.
Further, the property of the nucleic acid and the substance is the same as noted earlier.
Further, the tool of the diagnosis hypopharyngeal cancer includes but is not limited to chip, kit, test paper or high-flux sequence
Platform；High-flux sequence platform is a kind of tool of special diagnosis hypopharyngeal cancer, with the development of high throughput sequencing technologies, to one
The building of personal gene expression profile will become very easily work.By the gene table for comparing Disease and normal population
Up to spectrum, the exception for being easy to analyze which gene is related to disease.Therefore, the different of INCENP gene is known in high-flux sequence
The often purposes for also belonging to INCENP gene related to hypopharyngeal cancer, equally within protection scope of the present invention.
The present invention also provides a kind of tools for predicting hypopharyngeal cancer prognosis, and the prediction hypopharyngeal cancer prognostic tool includes can
In conjunction with INCENP gene nucleic acid or can in conjunction with INCENP albumen substance (such as antibody).The nucleic acid is able to detect
The mRNA level in-site of INCENP gene；The substance is able to detect the expression of INCENP albumen.
Further, the property of the nucleic acid and the substance is the same as noted earlier.
Further, the tool of the prediction hypopharyngeal cancer prognosis includes but is not limited to chip, kit, test paper or high throughput
Microarray dataset；High-flux sequence platform is a kind of tool of special diagnosis hypopharyngeal cancer, with the development of high throughput sequencing technologies,
Very easily work will be become to the building of the gene expression profile of a people.By the base for comparing Disease and normal population
Because of express spectra, the exception for being easy to analyze which gene is related to disease.Therefore, INCENP gene is known in high-flux sequence
The exception purposes for also belonging to INCENP gene related to hypopharyngeal cancer, equally within protection scope of the present invention.
The amino acid that anti-INCENP antibody used in testing product of the invention, diagnostic tool or its segment are identified
Number is not particularly limited, as long as antibody can combine INCENP.
The present invention also provides a kind of diagnosis hypopharyngeal cancer or the methods for predicting hypopharyngeal cancer prognosis, and the method includes walking as follows
It is rapid:
(1) sample of subject is obtained；
(2) expression of INCENP gene or albumen in Samples subjects is detected；
(3) it associates whether by the expression of the INCENP gene or albumen that measure with the illness of subject.
(4) compared with the control, the expression of INCENP gene or albumen reduces, then the subject is diagnosed as swallowing
Cancer or the subject are confirmed as prognosis mala.
The present invention also provides a kind for the treatment of methods of hypopharyngeal cancer, and the method includes activation INCENP gene or INCENP
Albumen.
Further, the method includes promoting the expression of INCENP gene, or the expression or enhancing of promotion INCENP albumen
The activity of INCENP albumen.
The present invention also provides a kind of screening techniques of tumour medicine, can be by after adding testing drug to cancer cell
Or the expression of some period measurement INCENP gene or INCENP albumen after applying testing drug to tumor model animal
Level improves the effect of tumor prognosis to measure tumour medicine.More specifically, when INCENP gene or INCENP albumen
It is swollen as improving that the drug may be selected when increasing after adding or applying testing drug or when restoring normal level in expression
The therapeutic agent of tumor prognosis.
The present invention also provides a kind of drugs of activator containing INCENP gene or INCENP albumen.
The present invention also provides application of the above-mentioned activator in the drug of preparation treatment hypopharyngeal cancer.
The activator of INCENP gene or INCENP albumen of the invention is unrestricted, as long as can promote or enhance
INCENP or be related to the upstream INCENP or downstream pathway substance expression or activity, and for treatment the effective drug of tumour be
It can.
Further, the activator includes INCENP gene, INCENP albumen, promoted type miRNA, promoted type transcriptional control
The factor or promoted type target small molecule compound.
The activator further includes carrier or host cell comprising carrying INCENP gene.
On the one hand activator of the invention can be used for supplementing the missing or deficiency of endogenic INCENP albumen, by mentioning
The expression of high INCENP albumen, thus hypopharyngeal cancer caused by treating because of INCENP hypoproteinosis.On the other hand can be used for enhancing
The activity of INCENP albumen, to treat hypopharyngeal cancer.
Drug of the invention can be used as medicine and be administered alone or apply together with other medicines.It can be with medicine of the invention
The other medicines that object is applied together are unrestricted, as long as it does not damage therapeutic or preventive medicine effect of the invention i.e.
It can, it is preferred that the drug for treating or preventing tumour may include such as alkylating agent, such as ifosfamide, ring phosphinylidyne
Amine, Dacarbazine, Temozolomide, Nimustine, busulfan, procarbazine, melphalan and Ranimustine；Antimetabolite, such as
Enocitabine, capecitabine, Carmofur, Cladribine, gemcitabine, cytarabine, cytarabine octadecyl phosphate
(cytarabine ocfosfate), Tegafur, tegafur-Uracil, Tegafur gimeracil oteracil potassium, deoxidation fluorine urine
Glycosides, hydroxycarbamide, fluorouracil, fludarabine, pemetrexed, Pentostatin, mercaptopurine and methotrexate (MTX)；Plant alkaloid, it is all
As Irinotecan, Etoposide, Sobuzoxane, docetaxel, nogitecan, Palmer altruism, vinorelbine, eldisine and
Vincaleukoblastinum；Antitumor antibiotic, such as actinomycin D, Aclarubicin, Amrubicin, idarubicin, epirubicin, Zinostatin
Stimalamer, daunorubicin, Doxorubicin, pirarubicin, bleomycin, Peplomycin, mitomycin C and mitoxantrone；
Drug based on platinum, such as oxaliplatin, carboplatin, cis-platinum and Nedaplatin；Hormonal medicaments, such as Anastrozole, Exemestane,
Estramustine, ethinyloestradiol, chlormadinone, Goserelin, tamoxifen, dexamethasone, Toremifene, Bicalutamide, Flutamide,
Prednisolone, Fosfestrol, mitotane, methyltestosterone, Medroxyprogesterone, Mepitiostane, Leuprorelin and Letrozole；Biological respinse modification
Agent, such as interferon-' alpha ', interferon beta, interferon gamma, interleukin, ubenimex, dry BCG and lentinan；With molecular targeted medicine
Object, such as Imatinib (imatinib), Gefitinib (gefitinib), gemtuzumab, ozogamicin, Tamibarotene, song
Appropriate monoclonal antibody, Tretinoin, bortezomib (bortezomib) and Rituximab etc..
Drug of the invention can be prepared into various dosage forms as needed.Including but not limited to, percutaneous, mucous membrane, nose, buccal,
Tablet, solution, granule, patch, paste, capsule, aerosol or suppository sublingual or orally use.
The administration method of drug of the invention is unrestricted, as long as it can play desired therapeutic effect or preventive effect i.e.
Can, including but not limited to intravenously, in peritonaeum, intraocularly, intra-arterial, intrapulmonary is taken orally, in vesicle, intramuscular, intratracheally, subcutaneously
, local by pleura by skin, sucking, by mucous membrane, skin, stomach is intra-articular, intra-ventricle, rectum, vagina,
In skull, in urethra, in liver, in tumor.In some cases, it can systematically be administered.It is locally to be administered in some cases.
The dosage of drug of the invention is unrestricted, can as long as obtaining desired therapeutic effect or preventive effect
To carry out appropriate determination according to symptom, gender, age etc..Example can be used in the dosage of therapeutic agent or prophylactic agent of the invention
Such as the therapeutic effect of disease or preventive effect are determined as index.
In the context of the present invention, " diagnosis hypopharyngeal cancer " both included judge subject whether suffered from hypopharyngeal cancer or
Including judging that subject whether there is the risk with hypopharyngeal cancer.
" treatment " used herein is covered treatment-related in such as mankind of the mammal with related disease or illness
Disease or morbid state, and include:
(1) prevent disease or morbid state occurs in mammals, especially when the mammal is susceptible in the disease
Diseased state, but when being not yet diagnosed with this morbid state；
(2) inhibit disease or morbid state, that is, prevent its generation；Or
(3) alleviate disease or morbid state, even if disease or morbid state subside.
Term " treatment " is usually directed to treatment mankind or animal (for example, being applied by animal doctor), wherein can reach certain pre-
The therapeutic effect of phase, for example, inhibiting the development (including reduce development speed, stop development) of illness, improving illness and healing
Illness.It further include the treatment as precautionary measures (such as prevention).To not yet development be illness but have development be the illness endanger
The purposes of the patient of danger, is also included in term " treatment ".
The advantages of the present invention:
Of the invention has found a kind of molecular marker for diagnosing hypopharyngeal cancer, can be in hypopharyngeal cancer using the molecular marker
The early stage of generation can be used as judging, provide the survival rate of patient.
In addition, the present invention is capable of providing significant information to determine treatment side for patient by the prognosis of prediction patient
Case strategy.
Of the invention includes that the therapeutic agent of the activator of INCENP gene or albumen can be used as the treatment of new hypopharyngeal cancer
Drug.
Detailed description of the invention
Fig. 1 shows the differential expression for studying INCENP gene in mRNA level in-site using QPCR；
Fig. 2 shows the differential expression for detecting INCENP gene on protein level using immunoblotting；
Fig. 3 is shown using QPCR the case where detecting INCENP gene overexpression in mRNA level in-site；
Fig. 4 is shown using immunoblotting the case where detecting INCENP gene overexpression on protein level；
Fig. 5 shows influence of the INCENP gene overexpression to hypopharynx cancer cell multiplication.
Specific embodiment
The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this
It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip
Part, such as Sambrook et al., molecular cloning: laboratory manual (New York:Cold Spring HarborLaboratory
Press, 1989) condition described in, or according to the normal condition proposed by manufacturer.
1 genetic chip of embodiment screens difference expression gene
1, it draws materials:
The primary Hypopharyngeal Cancer Patients operation excision cancerous tissue of 8 customary same period dissections, separately takes 9 non-hypopharyngeal cancers
The hypopharynx normal mucosa tissue of Disease is as control.All equal verified by postoperative pathology of cancerous tissue are hypopharyngeal cancer.It is all primary
The preoperative non-row Radiotherapy chemotherapy of Hypopharyngeal Cancer Patients, all cases complete clinical data.
2, the acquisition of RNA is organized
Total tissue RNA is extracted using Trizol one-step method.
3, the measurement of RNA purity and concentration
1 μ l of RNA solution, Instrument measuring OD260, OD280 are taken, RNA concentration is OD260 value × extension rate × 40/1000,
OD260/OD280 is calculated, ratio represents RNA solution purity is high in 1.7-2.0, -20 DEG C preservations few containing impurity such as protein.
4, RNA integrity detection
(1) 2 μ l RNA sample row, 1.5% agarose gel electrophoresis (80v, 15min) is taken；
(2) after separating zone, genefinder is dyed, and Zone electophoresis band is observed under blue light；
(3) as 28s/18s about 2:1, illustrate that RNA stablizes without degradation.
5, high-throughput transcript profile sequencing
The positioning of 5.1RNA-seq read
Low-quality read is removed to obtain cleaning read first, then using TopHat v1.3.1 will clean segment and
UCSC H.sapiens is matched with reference to genome (hg19), the H.sapiens UCSC hg19 editions indexes constructed in advance
It is downloaded from TopHat homepage, and as reference genome, when matching using TopHat with genome, allows each read (default
To 20) having multiple matching sites, most 2 mispairing.TopHat establishes possible according to exon region and GT-AG shear signal
Shearing site library navigates to the read for not navigating to genome on genome according to these shearing site libraries.We use
TopHat method system default parameter.
The assessment of 5.2 transcript abundances
The read file matched is handled by Cufflinks v1.0.3, and Cufflinks v1.0.3 is by RNA-seq piece
Number of segment mesh is standardized the relative abundance for calculating transcript.FPKM value refers to being matched in every 1,000,000 sequencing fragment specific
The segment number of the exon region of gene 1kb long.The confidence interval of FPKM estimated value is calculated by Bayesian inference method.
The GTF comment file for the reference that Cufflinks is used downloads (Homo_ from Ensembl database
sapiens.GRCh37.63.gtf)。
The detection of 5.3 difference expression genes
It is transferred to Cuffdiff by the Ensembl GTF file of downloading and by the matched original document of TopHat,
Cuffdiff re-evaluates the gene expression abundance for the transcript listed in GTF file using original matching files, detects difference table
It reaches.The only q value < 0.01 in Cuffidff output, test display is more just considered as successfully differential expression.
6, result
RNA-Sep the results show that filter out 211 differential expression bases altogether between hypopharynx cancerous tissue and normal control tissue
Cause, wherein expression up-regulation gene 54, expression lower gene 157.
2 large sample of embodiment verifies the difference expression gene filtered out
Based on high throughput transcript profile deep sequencing early period as a result, according to the size of P value, we select INCENP base
Because being verified.
1, sample collection
Hypopharynx cancerous tissue 45, normal control tissue 50 are collected according to the method for embodiment 1.
2, it is verified in mRNA level in-site
2.1 extract tissue RNA
Step is the same as embodiment 1.
2.2 reverse transcription
Reverse transcription uses Primescript 1stStrand cDNA synthesis kit kit, operating procedure are as follows
It carries out:
(1) following reaction liquid is added in microcentrifugal tube, as shown in table 1:
1 reaction liquid of table
| Reagent | Dosage |
| RNA | 2.0μg |
| dNTP | 1.0μl |
| Oligo(dT) | 2.0μl |
| Rnase free dH2O | Add to 10.0 μ l |
(2) 70 DEG C of incubation 5min, are rapidly cooled to 4 DEG C；
Following reaction reagent is added in microcentrifugal tube, reaction system is made:
The preparation of 2 reaction system of table
It gently shakes, after rapid centrifugation, 42 DEG C of reactions 1h, 70 DEG C of 10min terminate reaction, 4 DEG C of coolings, -20 DEG C of preservations.
Using SYBP Premix Ex TapTMII kit is carried out in Eppendorf Real-time PCR analyzer,
Concrete operations are as follows:
(1) following PCR reaction solution is prepared on ice:
The preparation of table 3PCR reaction solution
| Reagent | Dosage |
| SYBR | 10.0μl |
| Forward primer | 1.0μl |
| Reverse primer | 1.0μl |
| cDNA | 2.0μl |
| ddH2O | 6.0μl |
| Total amount | 20.0μl |
Primer sequence design is as follows:
INCENP gene:
5'-GGCTATCATTCACCAGTA-3'(SEQ ID NO.1)；
5’-ATATCCTCCAAGTCCAGT-3’(SEQ ID NO.2)
β-actin:
5'-GTGGGGCGCCCCAGGCACCA-3'(SEQ ID NO.3)；
5’-CTCCTTAATGTCACGCACGATTT-3’(SEQ ID NO.4)
(2) machine on executes following programs: 95 DEG C of initial denaturation 3min；95 DEG C of denaturation 15s.59 DEG C of annealing 20s, 72 DEG C of extensions
20s, totally 40 recycle.
As a result relative quantification method, formula 2 are used-△△ctIt calculates.Experiment is repeated 3 times.
△ ct=ct (A)-ct (β-actin)
△ △ ct=△ ct (experimental group)-△ ct (control group)
As a result as shown in Figure 1, compared with normal control tissue, the mRNA level in-site of INCENP gene is obvious in hypopharynx cancerous tissue
Decline, difference have statistical significance (P < 0.05).
3, it is verified on protein level
Each histone is extracted according to RIPA protein lysate kit specification, uses BCA determination of protein concentration kit
Protein concentration in test sample.With the detection INCENP albumen variation of conventional Western-blot method, each group experiment repeats 3
It is secondary, using β-actin as internal reference, INCENP protein band absorbance quantitative analysis is done, expression quantity is with INCENP albumen/β-actin
The ratio of absorbance represents.
As a result as shown in Fig. 2, compared with normal control tissue, INCENP protein level is significantly reduced in hypopharynx cancerous tissue,
Difference has statistical significance (P < 0.05).
Embodiment 3INCENP gene overexpression
1, plasmid construction
According to the coded sequence of INCENP gene design amplimer, primer be designed as those skilled in the art institute it is ripe
Know.From cDNA library (clontech company, the article No.: the 638831) coding of the INCENP gene of amplification overall length at Human fetal spleen
Sequence, above-mentioned cDNA sequence are inserted into eukaryotic expression vector pcDNA3.1, connect the recombinant vector pcDNA3.1- of acquisition
INCENP is used for subsequent experimental.
2, the culture and transfection of hypopharynx cancer cell
2.1 cell culture
Hypopharyngeal cancer FADU cell, which uses, contains 10% fetal calf serum (FBS), penicillin 100U/ml, 100 μ g/ml of streptomysin
1640 culture medium of RPMI be placed in 37 DEG C, 5%CO2, cultivate under saturated humidity environment.
2.2 cell transfecting
(1) day before transfection is by 0.5-2*105A tumour cell is suspended in the not antibiotic culture medium of 500 μ l, inoculation
To 24 well culture plates.
(2) transfection same day cell density should reach 80%-90%, prepare following compound A: 1 μ g Plasmid DNA is diluted in nothing
In blood serum medium, mix gently；Compound B: taking 4 μ l Lipofectamine2000 to be diluted in serum free medium, mixes
It is even.
(3) compound A and B are mixed, is mixed gently, is incubated at room temperature.
(4) 100 μ l liposome compounds are added in tumour cell, mix gently up and down, cell is put into 37 DEG C
Containing 5%CO2Incubator is incubated for 5-7 hours.
(5) it is small to continue culture cell 18-24 for the growth medium for adding 1ml to contain 2 times of normal serums and antibiotic concentration
When.
3, the overexpression situation of detection pcDNA3.1-INCENP is tested using QPCR
3.1 extraction cell total rnas are operated using conventional method.
3.2 reverse transcription
Step is the same as embodiment 2.
3.3QPCR
Step is the same as embodiment 2.
3.4 result
As a result as shown in figure 3, pcDNA3.1-INCENP can be successfully overexpressed, difference have statistical significance (P <
0.05)。
3, Western blot experiment detection pcDNA3.1-INCENP is overexpressed situation
Step is the same as embodiment 2.
As a result as shown in figure 4, transfecting INCENP in the cell of pcDNA3.1-INCENP compared with transfecting pcDNA3.1 group
The content of albumen obviously increases, and difference has statistical significance (P < 0.05).
Measurement of the expression of embodiment 4INCENP gene to hypopharyngeal cancer ability of cell proliferation
1, step:
Hypopharynx cancer cell FADU after transfecting 24 hours is inoculated in 96 porocyte culture plates, every hole 2*103A cell/
Hole/200 μ l, cell are grouped as follows:
Experimental group 1 (control group): hypopharyngeal cancer cell transfecting pcDNA3.1；
Experimental group 2: hypopharyngeal cancer cell transfecting pcDNA3.1-INCENP.
By cell in 37 DEG C, 5%CO2After incubator is incubated for 24 hours again, according to Brd U cell proliferation reagent box
The specification of (Chemicon International) measures cell proliferation rate.
2, statistical method
Experiment is completed according to being repeated 3 times, and result data is indicated in a manner of mean+SD,
Using SPSS13.0 statistical software come for statistical analysis, difference between the two is examined using t, it is believed that is had as P < 0.05
It is statistically significant.
3, result
As a result as shown in figure 5, compared to experimental group 1, the cells proliferation slowed down of experimental group 2, difference has statistical significance
(P<0.05).It is above-mentioned the experimental results showed that, INCENP expression can inhibit hypopharynx cancer cell multiplication.
Embodiment 5 detects influence of the INCENP gene expression to cell migration
1, experimental procedure is migrated
(1) by the cell dissociation after transfection for 24 hours, adjustment cell density is 105/ml；
600 μ L import fetal calf serums (FBS) are added in the every hole of (2) 24 porocyte culture plates, and the cell Transwell is placed in 24
Porocyte culture plates aperture, each 100 μ L RPMI, 1640 culture medium cell suspension of the small indoor addition of Transwell；
(3) 24 porocyte culture plates are incubated for for 24 hours, and the cell Transwell is taken out from 24 porocyte culture plates, discards culture
Base, PBS rinse the cell Transwell film portion attached cell；
(4) new 24 porocyte culture plates are taken, methanol/PBS mixed liquor ((1:1) 600 μ L, by Transwell is added in aperture
Cell is put into aperture, so that methanol/PBS mixed liquor is immersed upper chamber from lower room (24 porocyte culture plates aperture), is stored at room temperature
15min；
(5) methanol/PBS mixed liquor in the cell Transwell upper chamber and 24 porocyte culture plates apertures is discarded, lower room is added
The cell Transwell is placed in aperture, methanol is made to immerse upper chamber, room from lower room (24 porocyte culture plates aperture) by 600 μ L methanol
Temperature stands 15min；
(6) methanol is discarded, dries 15-30min at room temperature；
(7) it takes 0.1% crystal violet dye liquor, 600 μ L to instill 24 porocyte culture plates apertures, the cell Transwell is placed in small
Dye 15min in hole；
(8) 0.1% crystal violet dye liquor is discarded, distilled water flushing Transwell cell 15min is dried, seen under microscope
It examines, the different visuals field is taken to take pictures counting, experiment is repeated 3 times.
2, result
Average mobility cell number is respectively under transfection pcDNA3.1 group and the transfection each visual field of pcDNA3.1-INCENP group
(167.15 ± 13.92) are a and (84.41 soil 9.02) is a, and difference has statistical significance (P < 0.05).Above-mentioned experimental result table
It is bright, the migration of hypopharynx cancer cell of INCENP gene expression inhibition.
Embodiment 6 detects influence of the INCENP gene expression to cell invasion
1, Matrigel step
Matrigel is taken out from -20 DEG C of refrigerators before experimentTMMatrigel melts on ice chest, takes MatrigelTMMatrigel with
1640 culture medium of RPMI is mixed in 1:6 ratio, mixed liquor is made, the cell Transwell upper chamber is added, every 45 μ L of hole will
The cell Transwell is placed in 24 porocyte culture plates, is transferred to 37 DEG C of 5%CO2Incubator is incubated for 30min, subsequent cell inoculation
And culture operation is the same as above-mentioned Cell migration assay.After culture for 24 hours, Pei Ji is discarded, is gently wiped away on the cell Transwell with cotton swab
Indoor MatrigelTMMatrigel does not damage cell counterdie, the remaining same cell transfer experiments of operation.This experiment is repeated 3 times.
2, result
Average invasion cell number is respectively under transfection pcDNA3.1 group and the transfection each visual field of pcDNA3.1-INCENP group
(54.62 ± 5.87) are a and (28.35 soil 4.11) is a, and difference has statistical significance (P < 0.05).It is above-mentioned the experimental results showed that,
The invasion of hypopharynx cancer cell of INCENP gene expression inhibition.
The detection of 7 body outer clone Forming ability of embodiment
1, step
(1) cell suspension will be made after the cell dissociation after transfection for 24 hours, cell counting board counts；
1640 culture medium of 2ml 10%FBS-RPMI is added in the every hole of (2) six porocyte culture plates, close by 500/hole cell
Inoculating cell suspension is spent, is mixed gently；
(3) six porocyte culture plates move to 37 DEG C of 5%CO2Incubator is incubated for 10 days, replacement in every 3 days culture medium 1 time, every time
The hole 2ml/；
(4) after cultivating, culture medium is discarded, PBS buffer solution is carefully cleaned 3 times, each 5min, drying at room temperature, methanol
Fixed 15min discards methanol, the dry 20min of air at room temperature；
(5) take 0.1% crystal violet dye liquor that tissue culture plate is added, 1ml is added in every hole, dyes 15min；
(6) 0.1% crystal violet dye liquor is recycled, tissue culture plate distilled water cleans 15min；
(7) observation of taking pictures counts, and repeats test 3 times.
2, result
Transfecting pcDNA3.1 group average colony and forming number is respectively that (174.83 ± 15.48) are a, transfects pcDNA3.1-
It is that (79.84 soil 5.64) is a that INCENP group cell average colony, which forms number,.It is above-mentioned the experimental results showed that, INCENP gene expression
Inhibit the one-tenth knurl ability of hypopharynx cancer cell.
The explanation of above-described embodiment is only intended to understand method and its core concept of the invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will also be fallen into the protection scope of the claims in the present invention.
Claims (9)
1. the product for detecting INCENP gene or INCENP albumen is preparing the application in the tool for diagnosing hypopharyngeal cancer.
2. application according to claim 1, which is characterized in that the production of the detection INCENP gene or INCENP albumen
Product include the product for detecting the expression of INCENP gene or INCENP albumen.
3. application according to claim 1 or 2, which is characterized in that the product includes that can combine INCENP gene
Nucleic acid can be in conjunction with the substance of INCENP albumen；The nucleic acid is able to detect the expression of INCENP gene；The object
Matter is able to detect the expression of INCENP albumen.
4. application according to claim 3, which is characterized in that the nucleic acid is specifically expanded used in real-time quantitative PCR
Increase the primer of INCENP gene, the primer sequence is as shown in SEQ ID NO.1 and SEQ ID NO.2.
5. application according to claim 1, which is characterized in that the tool include be able to detect INCENP gene or
The tool of the expression of INCENP albumen.
6. application according to claim 5, which is characterized in that the tool includes can be in conjunction with the nucleic acid of INCENP gene
Or it can be in conjunction with the substance of INCENP albumen；The nucleic acid is able to detect the expression of INCENP gene；The substance energy
Enough detect the expression of INCENP albumen.
7. application according to claim 6, which is characterized in that the nucleic acid is specifically expanded used in real-time quantitative PCR
Increase the primer of INCENP gene, the primer sequence is as shown in SEQ ID NO.1 and SEQ ID NO.2.
Application of the activator of 8.INCENP gene or INCENP albumen in the drug of preparation treatment hypopharyngeal cancer.
9. application according to claim 8, which is characterized in that the activator can promote or enhance INCENP or be related to
The expression or activity of the substance of the upstream INCENP or downstream pathway.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610601139.0A CN105969903B (en) | 2016-07-27 | 2016-07-27 | The diagnosis and treatment product of hypopharyngeal cancer biomarker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610601139.0A CN105969903B (en) | 2016-07-27 | 2016-07-27 | The diagnosis and treatment product of hypopharyngeal cancer biomarker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105969903A CN105969903A (en) | 2016-09-28 |
| CN105969903B true CN105969903B (en) | 2019-09-27 |
Family
ID=56951048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610601139.0A Active CN105969903B (en) | 2016-07-27 | 2016-07-27 | The diagnosis and treatment product of hypopharyngeal cancer biomarker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105969903B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005278472A (en) * | 2004-03-29 | 2005-10-13 | Pharma Design Inc | Aurora b coupling factor incenp |
-
2016
- 2016-07-27 CN CN201610601139.0A patent/CN105969903B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005278472A (en) * | 2004-03-29 | 2005-10-13 | Pharma Design Inc | Aurora b coupling factor incenp |
Non-Patent Citations (3)
| Title |
|---|
| Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer.;Guangying Qi et al.;《Virchows Arch》;20071231;297-302 * |
| Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells.;Adams et al.;《Chromosoma》;20010330;65-74 * |
| Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.;Kabisch et al.;《Carcinogenesis》;20151231;第36卷(第2期);256-271 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105969903A (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105969901B (en) | Purposes of the MS4A6A as Huppert's disease diagnosis and treatment marker | |
| CN105907879B (en) | Carcinoma of endometrium biomarker | |
| CN106222259B (en) | A kind of molecular marker of diagnosis and treatment Huppert's disease | |
| CN106906290B (en) | CDSN as diagnosis and treatment target of tongue squamous cell carcinoma | |
| CN106244705B (en) | Application of the ERC1 in preparation diagnosis or treatment hypopharyngeal cancer tool | |
| CN105969904B (en) | Huppert's disease biomarker | |
| CN106011289B (en) | The diagnosis and treatment target of LILRA2 gene and its expression product as Huppert's disease | |
| CN106381329B (en) | The diagnosis and treatment target of C18orf8 gene and its expression product as hypopharyngeal cancer | |
| CN106011288B (en) | Huppert's disease diagnosis and treatment marker and its application | |
| CN106947820B (en) | Application of VCAN in diagnosis and treatment of colon adenocarcinoma | |
| CN106191283B (en) | The diagnosis and treatment product of Huppert's disease biomarker | |
| CN106011260B (en) | A kind of molecular marker of diagnosis and treatment carcinoma of endometrium | |
| CN106011291B (en) | A kind of molecular marker of diagnosis and treatment hypopharyngeal cancer | |
| CN106947818A (en) | A kind of molecular marker of diagnosis and treatment adenocarcinoma of colon | |
| CN105969903B (en) | The diagnosis and treatment product of hypopharyngeal cancer biomarker | |
| CN106119357B (en) | Application of the TNS11 in preparation diagnosis and treatment carcinoma of endometrium product | |
| CN106011286B (en) | Hypopharyngeal cancer diagnosis and treatment marker and its application | |
| CN106119399B (en) | Purposes of the ZNF385C as hypopharyngeal cancer diagnosis and treatment marker | |
| CN106119358B (en) | The diagnosis and treatment product of carcinoma of endometrium biomarker | |
| CN107034270B (en) | CLIC3 as diagnosis and treatment target of lung adenocarcinoma | |
| CN106222257B (en) | Application of the IGSF6 in preparation diagnosis and treatment Huppert's disease product | |
| CN107034272B (en) | Application of CXCL2 in preparation of tool for diagnosing or treating lung adenocarcinoma | |
| CN107034271B (en) | Purposes of the DUOX1 as adenocarcinoma of lung diagnosis and treatment marker | |
| CN106947819A (en) | Adenocarcinoma of colon diagnosis and treatment mark | |
| CN106048031B (en) | Application of the SYNM in preparation diagnosis or treatment carcinoma of endometrium tool |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant after: Beijing Yang Shen biology information technology company limited Address before: 100080 Beijing city Haidian District Shanyuan Street No. 1 cubic court building room 3103 Applicant before: Beijing Yang Shen biology information technology company limited |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211125 Address after: 266000 room 2503, Qianshan building, D2, Qingdao International Innovation Park Phase II, No.1 Keyuan Weiyi Road, Laoshan District, Qingdao City, Shandong Province Patentee after: Qingdao Yangshen biomedical Co.,Ltd. Address before: Room 1210, building 3, Ronghua Xintai building, 10 ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Patentee before: BEIJING MEDINTELL BIOMED Co.,Ltd. |
|
| TR01 | Transfer of patent right |